- Conditions
- Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 53
- States / cities
- Bakersfield, California • Encino, California • Glendale, California + 49 more
Recruitment Status
Active, not recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10510
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 361–372 of 10,510 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Psoriasis
- Interventions
- Guselkumab, Placebo for guselkumab, Etanercept
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 10
- States / cities
- Palo Alto, California • San Diego, California • Macon, Georgia + 7 more
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Refractory Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Other · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Arthritis, Psoriatic
- Interventions
- Icotrokinra, Placebo, Active reference comparator
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Jonesboro, Arkansas • DeBary, Florida • Plantation, Florida + 6 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Epcoritamab, Investigator's Choice Chemotherapy
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 15
- States / cities
- Indianapolis, Indiana • Lexington, Kentucky • Jackson, Michigan + 10 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Miami, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab, Daratumumab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Norwalk, Connecticut + 30 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD
- Interventions
- Ensifentrine, Placebo, LABA/LAMA
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Ann Arbor, Michigan • Pittsburgh, Pennsylvania
- Conditions
- Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor, Interstitial Cystitis, Congenital Abnormalities, End Stage Renal Disease, Renal Tumor, Kidney Injury
- Interventions
- RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 6
- States / cities
- Duarte, California • Chicago, Illinois • New York, New York + 3 more
- Conditions
- Fistulizing Crohns Disease, Perianal Crohns Disease
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen-Cilag Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 12 more
- Conditions
- Suicide and Depression, Adolescent Behavior
- Interventions
- iCHART, Treatment As Usual
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 765 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Gibbsboro, New Jersey • Johnstown, Pennsylvania • Philadelphia, Pennsylvania + 4 more
- Conditions
- Atopic Dermatitis
- Interventions
- APG777, Placebo
- Drug
- Lead sponsor
- Apogee Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more